CVS Health (CVS)
(Delayed Data from NYSE)
$56.11 USD
-0.83 (-1.46%)
Updated Sep 11, 2024 03:59 PM ET
After-Market: $56.07 -0.04 (-0.07%) 7:52 PM ET
4-Sell of 5 4
A Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$56.11 USD
-0.83 (-1.46%)
Updated Sep 11, 2024 03:59 PM ET
After-Market: $56.07 -0.04 (-0.07%) 7:52 PM ET
4-Sell of 5 4
A Value D Growth F Momentum C VGM
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
CVS Health Beats on Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Currently, CVS Health has a Zacks Rank #3 (Hold) but that could change following its first quarter 2017 earnings report which has just released.
Rite Aid (RAD) Stock Up on Better-than-Expected Q4 Results
by Zacks Equity Research
Rite Aid (RAD) posted fourth-quarter fiscal 2017 results.
CVS Health Launches Reduced Rx for Affordable Medication
by Zacks Equity Research
CVS Health Corporation (CVS), a leading name in pharmacy benefit and retail pharmacy, recently announced the launch of a prescription savings program-Reduced Rx.
CVS Health (CVS) Up 4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CVS Health Adopts Epic EHR for Specialty Care Programs
by Zacks Equity Research
CVS Health Corporation (CVS) recently announced that it has chosen Epic as the electronic health record (EHR) system for CVS Specialty's care management programs.
CVS Health (CVS) Beats on Q4 Earnings, Retains '17 View
by Zacks Equity Research
CVS Health Corporation (CVS) reported fourth-quarter 2016 adjusted earnings per share (EPS) of $1.71, up 11.8% year over year.
CVS Health Tops Q4 Earnings, Misses on Revenues
by Zacks Equity Research
CVS Health posted mixed fourth quarter results with earnings beating the Zacks Consensus Estimate while sales missed the mark.
Paycom Software (PAYC) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Paycom Software, Inc. (PAYC) is set to report fourth-quarter 2016 results on Feb 8.
Broadridge Financial (BR) Q2 Earnings: What's in Store?
by Zacks Equity Research
Broadridge Financial Solutions Inc. (BR) is set to report fiscal second-quarter 2017 results on Feb 8.
CDW Corp. (CDW) Q4 Earnings: What's in the Cards this Time?
by Zacks Equity Research
CDW Corp. (CDW) is set to report fourth-quarter 2016 results on Feb 7.
Marsh & McLennan (MMC): Will it Disappoint in Q4 Earnings? (Revised)
by Zacks Equity Research
Marsh & McLennan Companies, Inc. (MMC) is scheduled to report fourth-quarter and full-year 2016 results on Feb 2.
Can Cigna (CI) Sustain its Earnings Surprise Streak in Q4? (Revised)
by Zacks Equity Research
We expect Cigna Corp. (CI) to beat earnings expectations when it reports fourth-quarter and full-year 2016 results, on Feb 2.
Marsh & McLennan (MMC): Will it Disappoint in Q4 Earnings?
by Zacks Equity Research
Marsh & McLennan Companies, Inc. (MMC) is scheduled to report fourth-quarter and full-year 2016 results on Feb 2.
Can Cigna (CI) Sustain its Earnings Surprise Streak in Q4?
by Zacks Equity Research
We expect Cigna Corp. (CI) to beat earnings expectations when it reports fourth-quarter and full-year 2016 results, on Feb 2.
Rite Aid Down on Walgreens Deal Offer Price Cut & Delay
by Zacks Equity Research
Rite Aid Corp. (RAD) and Walgreens Boots Alliance Inc. (WBA) jointly agreed upon a Jul 31, 2017 deadline for the deal and slashed the offer price to accommodate more store divestitures that would help gain regulatory approval.
Paylocity Holding (PCTY) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Paylocity Holding Corporation (PCTY) is set to report second-quarter fiscal 2017 results on Feb 2.
Teladoc (TDOC) to Report Q4 Earnings: What's in Store? (revised)
by Zacks Equity Research
Telehealth provider Teladoc Inc. (TDOC) has not confirmed the time/date for its December-quarter earnings release yet, but the report will likely be fairly soon, as they last reported quarterly results on October 27, 2016.
NXP Semiconductors (NXPI) Q4 Earnings: Will it Surprise?
by Zacks Equity Research
NXP Semiconductors NV (NXPI) is set to report fourth-quarter 2016 results on Feb 1.
CVS Health (CVS) Q4 Earnings: A Beat in Store for the Stock?
by Zacks Equity Research
We expect pharmacy innovation company CVS Health Corporation (CVS) to beat expectations when it reports fourth-quarter 2016 results on Feb 9.
Teladoc (TDOC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Telehealth provider, Teladoc Inc. (TDOC ) is scheduled to report fourth-quarter and full-year 2016 results on Jan 27.
Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlighted as Zacks Bull and Bear of the Day
CVS Debuts Cheap EpiPen Alternative
by Madeleine Johnson
On Thursday, leading drug store chain CVS Health Corp. (CVS) announced that it is now selling a cheaper alternative to Mylan's (MYL) EpiPen.
Rite Aid (RAD) Q3 Earnings Lag, Walgreens Merger on Track
by Zacks Equity Research
Rite Aid (RAD) posted dismal third-quarter fiscal 2016 results.
CVS Health (CVS) Down on Prevailing Risks, Tepid Guidance
by Zacks Equity Research
In Dec 19, 2016, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS)
CVS Health Revises View for 2016 & 2017, Declares Dividend
by Zacks Equity Research
CVS Health Corporation (CVS) recently announced strategies to drive long-term growth and shareholders' value.